New appointments at Aragon Pharmaceuticals
This article was originally published in Scrip
Aragon Pharmaceuticals (US), privately held small-molecule drug discovery company identifying medicines for the treatment of hormonally driven cancers, has appointed Dr Richard Heyman chief executive officer, and has elected Dr Ronald Evans and Dr David Mangelsdorf to its scientific advisory board. Dr Heyman has 20 years' drug discovery experience in the biotech sector, having most recently co-founded Aragon in 2009. Before that, he was chief scientific officer at Kalypsys, where he conducted drug discovery in therapeutic areas including metabolic diseases, pain and inflammation. Dr Evans is professor in the gene expression laboratory and March of Dimes Chair in molecular and developmental biology at the Salk Institute for Biological Studies in La Jolla, California, while Dr Mangelsdorf has been at the University of Texas Southwestern Medical Center in Dallas, where he has been professor and chair of the department of pharmacology, since 1993.